.Competing passions.R.S., M.S., H.G. and A.A.R. are planners of the 1M1M campaign. H.G. and A.A.R. are actually panel of directors participants as well as R.S., M.S. as well as A.A.R. are actually participants of the medical advisory committee of N1C. A.A.R. makes known work by LUMC, which has patents on exon-skipping technology, several of which has actually been accredited to BioMarin as well as consequently sublicensed to Sarepta. As co-inventor of some of these licenses, A.A.R. was qualified to a portion of royalties. A.A.R. further reveals functioning as ad hoc professional for PTC Therapies, Sarepta Therapeutics, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Before 5 years, A.A.R. also executed impromptu speaking with for Alpha Anomeric. A.A.R. additionally discloses subscription of the medical advisory boards of Eisai, Hybridize Therapeutics, Silence Rehabs, Sarepta Therapeutics, Sapreme and Mitorx. In the past 5 years, A.A.R. was actually additionally a medical board of advisers participant for ProQR. Commission for A.A.R. u00e2 s consulting and also urging activities is spent to LUMC. Before 5 years, LUMC also got speaker honoraria from PTC Therapies, Alnylam Netherlands, Italfarmaco and also Pfizer and funding for contract investigation from Sapreme, Eisai, Galapagos, Synaffix and also Alpha Anomeric. Project funding is received coming from Sarepta Therapeutics as well as Entrada via unregulated gives. H.G. has nothing to divulge in connection with the subjects covered in this particular manuscript. Before 5 years, he has actually also acquired consultancy gratuity from UCB. M.S. acquired working as a consultant honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa previously 5 years, all irrelevant to the present composition. R.S. has nothing to disclose in connection with the subject matters dealt with in this particular manuscript. She has obtained audio speaker and/or working as a consultant honoraria or financing payments from Abbvie, Bial, STADA and also Everpharma over the last 5 years.